Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
Molecular Partners announced the publication of positive Phase 1 clinical trial data for MP0317, a tumor-localized CD40 agonist, demonstrating effective tumor microenvironment modulation and a favorable safety profile in advanced cancer patients. The data support further clinical trials, including an ongoing Phase 2 study in cholangiocarcinoma, com…